A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

NCT01585350 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)
BIOLOGICAL: MELITAC 12.1 + Montanide ISA-51 + polyICLC

Sponsor

Craig L Slingluff, Jr

Collaborators

[object Object]
[object Object]
[object Object]